We use the latest technologies to optimize the manufacturing processes
Innovation in biotechnology
IBES® (Improved Baculovirus Expression System*)
IBES® uses an in vivo expression system in which insect larvae are used as living bioreactors, being an efficient system to produce functional recombinant proteins, with clear advantages over the more traditional expression systems (E. coli, yeast, insect cell culture, etc.).
Our offer:
We are able to supply you with the amount of recombinant protein you require.
We can scale up your manufacturing expression procedure and implement your purification and characterisation processes.
Main advantages:
- Large production capability
- Significantly shortened production time
- Flexibility
- Linear scaling-up of production
- High batch-to-batch reproducibility
- Optimal recombinant protein conformation
- Cost reduction in fixed investments
*Licensed by Algenex, S.L
Innovation in biotechnology
Non-plasma-based calibrators and controls
In OEM Technology Center we decided to explore alternative and innovative methods of developing calibrators and controls for a new IVD immunoassay. With this goal in mind, we partnered with ArkAb to develop human chimeric antibodies that would mimic the native antibodies found in a disease state in human plasma. In order to obtain the human chimeric antibodies, the OEM Technology Center supplied the recombinant antigens that are being used in our IVD assay.
Our offer:
We are able to supply our partners with chimeric-based calibrators and controls that are equivalent to plasma-based calibrators and controls.
Main advantages:
- Availability of the key raw material
- Large production capability
- High batch-to-batch reproducibility
- Linear scaling-up of production
Innovation in biotechnology
Monoclonal antibodies against small-size molecules
Obtaining good monoclonal antibodies (mAbs) against a small-sized molecule is a challenge since the immunogenicity of small molecules is typically low. The performance of available mouse monoclonal antibodies (mAbs) against a specific small molecule has room for improvement, particularly when focusing on increasing the affinity of the antibody for the small-molecule target.
For this reason, we seized the opportunity to collaborate with an innovative company in order to validate the use of a novel mAb in a next-generation immunoassay to detect valproic acid, a small molecule for therapeutic use. SYnAbs can generate mAbs from species other than mice.
Our offer:
We are able to supply our partners with the right biomaterial to detect small-size molecules with high affinity.
Innovation in biotechnology
Increasing our knowledge of BSA for immunoassay use
The Werfen Innovation and Biotechnology team at the OEM Technology Center has characterized different BSA batches from different manufacturers, as well as a control batch of BSA, using RedShiftBio® Microfluidic Modulation Spectroscopy (MMS) technology. This technology allows higher-order protein structure differences lower than 2% to be distinguished automatically and in a more reproducible way than other traditional methods.